Abstract: A condensed heterocyclic compound having the formula (I): ##STR1## wherein A and B are both carbonyl groups of one thereof represents a methylene group and the other represents a carbonyl group; Z represents an oxygen atom, a sulfur atom, a substituted or unsubstituted nitrogen atom, or a methylene group; n is an integer of 2 to 6; and R represents a group having the following formula: ##STR2## wherein R.sup.1 represents a hydrogen atom or a hydroxyl group; R.sup.2 represents a substituted or unsubstituted phenyl or 2-pyridyl group or salts thereof.The compounds according to the present invention exhibit a strong affinity to the .sigma.-receptor and are useful as psychopharmaceuticals.

Abstract: A therapeutic agent for alleviating disorders caused by nerve cell degeneration in the brain which contains a cyclopropachromen derivative represented by the following general formula (I): ##STR1## wherein n is an integer of from 2 to 5;the carbon atom in the --(CH.sub.2).sub.n -- moiety may be optionally substituted with a methyl group or a hydroxyl group;R.sup.1 and R.sup.2 independently represent a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or an aralkyl group having 7 to 10 carbon atoms; or alternatively R.sup.1 and R.sup.2 form together with the nitrogen atom to which they are attached, a morpholino group, a thiomorpholino group, a pyrrolidinyl group, a piperidinyl group, a homopiperidinyl group, a piperazinyl group, a homopiperazinyl group, an N-alkylpiperazinyl group, N-alkylhomopiperazinyl group, an N-hydroxyalkylpiperazinyl group or a pyrrolidonyl group or alternatively R.sup.1 and R.sup.

Abstract: A benzoxazepine derivative suitable for use as a psychotropic composition having the formula: ##STR1## wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, R represents an aromatic group or a heterocyclic group, which may be substituted, X represents a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.5 lower alkyl group, a C.sub.1 -c.sub.5 lower alkoxy group, a C.sub.7 -C.sub.9 arylalkoxy group, a hydroxyl group, a nitro group, or an ester group, and n is an integer of 2 to 10 and salts thereof.

Abstract: 1. A compound having the formula (I): ##STR1## wherein A is --CH.sub.2 --, --O--, or --S--; R.sup.1 is CH.sub.3 or OCH.sub.3 ; R.sup.2 is hydroxy of carboxy which may be optionally esterized or amidated; R.sup.3 is H or a lower alkyl; and n is 0 or an integer of 1 to 6 or a pharmaceutically acceptable sale thereof.

Abstract: A benzoxepin derivative represented by the formula (I): ##STR1## wherein R represents a heterocyclyc group, and salts thereof; a process for production thereof comprising the steps of reducing an oxime represented by the formula (V): ##STR2## wherein R has the same meaning as defined in the formula (I), and hydrolyzing the intermediate produced of the above reduction; and pharmaceuticals comprising the compound (I).

Abstract: A hydroquinonylphenyl butyric acid amide derivative having the formula (I): ##STR1## wherein R.sup.1 represents an aromatic or heterocyclic group which may be substituted, R.sup.2 represents a hydrogen atom, a lower alkylcarbonyl group, an aromatic carbonyl or heterocyclic carbonyl group which may be substituted, and X represents an oxygen atom or sulfur atom or a pharmaceutically acceptable salt thereof, which has a cerebral insufficiency improving activity.

Abstract: 2-phenylbenzoxepin derivatives having a hypoglycemic activity, hypotensive activity, and platelet coagulation inhibiting activity, a process for production of the derivatives, and pharmaceutical compositions containing the derivatives.

Abstract: A derivative of benzoquinonylphenyl alkanoic acid amide having the formula: ##STR1## wherein X represents an oxygen atom, sulfur atom, or methylated nitrogen atom, Me represents methyl, and n is 2 or 3. This derivative is effective as a cerebral insufficiency improver.

Abstract: An ailanthone derivative having the general formula: ##STR1## wherein R is a p-alkyl benzoic acid residue having 8 to 21 carbon atoms, a 2-methyl saturated fatty acid residue having 6 to 19 carbon atoms, a 2-methyl-2-unsaturated fatty acid residue having 4 to 19 carbon atoms, a 3,4-dimethyl-4-acyloxy-2-pentenoic acid residue having 9 to 19 carbon atoms, a 3,4,4-trimethyl-2-unsaturated fatty acid residue having 8 to 21 carbon atoms, a group having the formula ##STR2## wherein n is an integer of 1 to 13, a group having the general formula ##STR3## wherein n is an integer of 1 to 13, a trans-cinnamic acid residue, a linear saturated fatty acid residue having 3 to 22 carbon atoms, a 3-methyl-2-unsaturated fatty acid residue having 6 to 19 carbon atoms, a 3,4-dimethyl-2-unsaturated fatty acid residue having 7 to 20 carbon atoms, a terpenic acid residue, a 2-amino saturated fatty acid residue having 2 to 18 carbon atoms or a salt thereof, a 2-hydroxy saturated fatty acid residue having 3 to 18 carbon atoms, or a 3,

Abstract: A diaryl butyric acid derivative having the general formula: ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, or an acyl group having 2 to 4 carbon atoms; R.sup.2 represents an alkyl group having 1 to 3 carbon atoms; andX represents a variety of substituents.This diaryl butyric acid derivative or the pharmaceutically acceptable salt thereof can be prepared by reacting a benzoxepin derivative having the general formula: ##STR2## wherein R.sup.2 is the same as defined above with an amine or alcohol derivative having the general formula;X--Hwherein X is the same as defined above in the presence of an acid catalyst at room temperature or at an elevated temperature and, optionally, further reading the reaction product with an alkylation agent having 1 to 3 carbon atoms or an acylation agent having 2 to 4 carbon atoms.

Abstract: The present invention relates to a novel oxabicycloheptane derivative of the following formula and a pharmaceutically acceptable salt thereof: ##STR1## where D is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group, an arylalkoxy group, an acyloxy group, a dialkylcarbamoyloxy group or an amidoalkyloxy group; B is a substituted or unsubstituted phenyl, thienyl or furyl group; A is the group ##STR2## (where l is 0 or 1; m and n are each 1 or more, provided that m+n is an interger of 2-8; R.sup.1 is an alkylamino group, a dialkylamino group, an arylalkylamino group, a morpholino group, a thiomorpholino group, a 1-pyrrolidinyl group, a piperidino group, an N-alkylpiperazinyl group, an N-hydroxyalkylpiperazinyl or a pyrrolizidinyl group; and R.sup.2 is a lower alkyl group or a hydroxl group), or the group ##STR3## (where l, m, n, R.sup.1 and R.sup.2 are each the same as defined above), or the group ##STR4## (where R.sup.3 and R.sup.